



Corrigendum: Low-Dose Total Body Irradiation Can Enhance Systemic Immune Related Response Induced by Hypo-Fractionated Radiation

Jing Liu^{1†}, Jie Zhou^{2†}, Min Wu^{1†}, ChuanFei Hu¹, Juan Yang¹, Dong Li¹, Peng Wu¹, Yue Chen³, Ping Chen¹, Sheng Lin¹, YongXia Cui¹, ShaoZhi Fu^{1*} and JingBo Wu^{1*}

¹ Department of Oncology, The Affiliated Hospital of Southwest Medical University, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China, ² Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, ³ Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China

OPEN ACCESS

Edited and reviewed by:

Franz Rödel,
University Hospital Frankfurt, Germany

*Correspondence:

JingBo Wu
wjb6147@163.com

ShaoZhi Fu
shaozhifufu513@163.com

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Immunology

Received: 22 July 2021

Accepted: 06 August 2021

Published: 03 September 2021

Citation:

Liu J, Zhou J, Wu M, Hu C, Yang J, Li D, Wu P, Chen Y, Chen P, Lin S, Cui Y, Fu S and Wu J (2021)

Corrigendum: Low-Dose Total Body Irradiation Can Enhance Systemic Immune Related Response Induced by Hypo-Fractionated Radiation.

Front. Immunol. 12:745787.
doi: 10.3389/fimmu.2021.745787

Keywords: systemic immune related response, hypo-fractionated radiation therapy, low-dose total body irradiation, immune enhancement, immunosuppressive microenvironment

A Corrigendum on

Low-Dose Total Body Irradiation Can Enhance Systemic Immune Related Response Induced by Hypo-Fractionated Radiation

By Liu J, Zhou J, Wu M, Hu C, Yang J, Li D, Wu P, Chen Y, Chen P, Lin S, Cui Y, Fu S and Wu J (2019). *Front. Immunol.* 10:317. doi: 10.3389/fimmu.2019.00317

In the original article, there was a mistake in **Figures 3C** and **4C** as published. The authors regret that the wrong images were used. The reason may be owing to layer fusion leading the images to be duplicated (primary tumor and secondary tumor images were repeated in the L-TBI group; secondary tumor images were repeated in the control group and L-TBI group). The corrected **Figures 3** and **4** appear below. Furthermore, the authors have ensured that the arrows now point to identifiable structures within the images. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Liu, Zhou, Wu, Hu, Yang, Li, Wu, Chen, Chen, Lin, Cui, Fu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.




FIGURE 3 | Effect of combination H-RT and L-TBI therapy on apoptosis in 4T1 tumor bearing tissues. **(A)** Comparison of representative TUNEL IHC-stained in different treatment groups. **(B)** Percentage of TUNEL positive cells in the primary and secondary tumor. **(C)** Representative gamma-H2AX IHC staining image in different treatment groups. **(D)** Percentage of gamma H2AX positive cells in the primary and secondary tumor. The arrows point to the TUNEL and gamma-H2AX positive cells in the tumor tissue (original magnification $\times 200$). Data are expressed as mean \pm SE of 5 mice/group. (* $P < 0.05$, ** $P < 0.01$, and NS, not significant).




FIGURE 4 | Comparison of CD3+ and CD86+ lymphocytes in different treatment groups. **(A)** Representative images of CD3 IHC in tumor tissues of different treatment groups. **(B)** Percentage of CD3 positive cells in the primary and secondary tumor. **(C)** Representative IHC images of CD86 infiltration in the tumor tissue of different treatment groups. **(D)** Percentage of CD86 positive cells in the primary and secondary tumor. The arrows point the CD3 and Cd86 positive cells in tumor tissues from mice that received different treatments (original magnification $\times 200$). Data are expressed as mean \pm SE of 5 mice/group. (*P < 0.05, **P < 0.01, ***P < 0.001, and NS, not significant).